Itolizumab

Rediff.com » News » Itolizumab

News for Itolizumab

News
Business

Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Biotechnology major Biocon on Monday said it will launch biologic drug Itolizumab for the treatment of moderate to severe COVID-19 patients at a price of around 8,000 per vial. The company......

Biocon drug gets nod for use in moderate to severe COVID-19 patients

Biotechnology major Biocon on Saturday announced that its 'breakthrough drug', Itolizumab has received Drugs Controller General of India's (DCGI) approval for its use in moderate to......

Drug controller okays Psoriasis injection for COVID-19 patients

India's drug regulator has approved Itolizumab, used to cure skin ailment psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, officials......

'No preparedness planning, no accountability, no action plan'

'This government did not have any plan for safety stocks of essential medicines.' IMAGE: Doctors attend to a patient suffering from COVID-19 inside the emergency room at the Safdarjung Hospital in......

Maharashtra, TN account for 50% of active COVID-19 cases: Govt

With the number of COVID-19 cases crossing the nine lakh-mark on Tuesday, the health ministry said that 86 per cent of the total active cases are confined to 10 affected states with Maharashtra and......

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.......

How Biocon plans to fight COVID-19

'I cannot cope with the demand. It will take us a couple of months to ramp up production.' Bio-pharmaceutical company Biocon, which saw a decline in its profit in Q1FY21 despite a double digit......

Itolizumab

News for Itolizumab

Itolizumab, new drug for COVID-19 patients to cost Rs 8,000 per vial

Biocon drug gets nod for use in moderate to severe COVID-19 patients

Drug controller okays Psoriasis injection for COVID-19 patients

'No preparedness planning, no accountability, no action plan'

Maharashtra, TN account for 50% of active COVID-19 cases: Govt

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

How Biocon plans to fight COVID-19

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS